Vera Therapeutics (VERA) Competitors $22.29 +0.27 (+1.23%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$22.28 -0.01 (-0.04%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA vs. NUVL, MRUS, CRSP, TGTX, CYTK, AAPG, KRYS, ACAD, ADMA, and TLXShould you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), Ascentage Pharma Group International (AAPG), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry. Vera Therapeutics vs. Its Competitors Nuvalent Merus CRISPR Therapeutics TG Therapeutics Cytokinetics Ascentage Pharma Group International Krystal Biotech ACADIA Pharmaceuticals ADMA Biologics Telix Pharmaceuticals Nuvalent (NASDAQ:NUVL) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Which has preferable earnings and valuation, NUVL or VERA? Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.90-15.51Vera TherapeuticsN/AN/A-$152.15M-$3.58-6.23 Do institutionals and insiders have more ownership in NUVL or VERA? 97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by company insiders. Comparatively, 16.3% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer NUVL or VERA? In the previous week, Nuvalent had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 12 mentions for Nuvalent and 10 mentions for Vera Therapeutics. Nuvalent's average media sentiment score of 1.56 beat Vera Therapeutics' score of 1.33 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vera Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NUVL or VERA more profitable? Nuvalent's return on equity of -32.58% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -32.58% -30.14% Vera Therapeutics N/A -46.70%-39.46% Do analysts prefer NUVL or VERA? Nuvalent currently has a consensus target price of $120.80, indicating a potential upside of 58.91%. Vera Therapeutics has a consensus target price of $63.00, indicating a potential upside of 182.64%. Given Vera Therapeutics' higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Vera Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Which has more risk and volatility, NUVL or VERA? Nuvalent has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. SummaryNuvalent beats Vera Therapeutics on 7 of the 13 factors compared between the two stocks. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERA vs. The Competition Export to ExcelMetricVera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41B$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-6.2321.0831.2726.59Price / SalesN/A350.65433.65155.40Price / CashN/A44.6737.7359.36Price / Book3.048.0910.176.68Net Income-$152.15M-$54.08M$3.27B$265.59M7 Day Performance-1.24%-0.41%1.39%0.62%1 Month Performance7.58%6.23%6.19%2.61%1 Year Performance-39.40%10.45%43.79%22.34% Vera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERAVera Therapeutics3.8439 of 5 stars$22.29+1.2%$63.00+182.6%-39.3%$1.41BN/A-6.2340Positive NewsNUVLNuvalent3.4335 of 5 stars$74.05-2.7%$118.91+60.6%-10.2%$5.49BN/A0.0040News CoveragePositive NewsMRUSMerus2.1534 of 5 stars$65.74-2.6%$88.64+34.8%+27.7%$5.10B$36.13M-11.9537News CoveragePositive NewsCRSPCRISPR Therapeutics3.673 of 5 stars$54.13-0.3%$71.60+32.3%+11.7%$4.94B$37.31M0.00460Analyst UpgradeTGTXTG Therapeutics4.4118 of 5 stars$28.53-3.1%$46.25+62.1%+24.0%$4.67B$329M77.11290Positive NewsCYTKCytokinetics3.7558 of 5 stars$37.01-3.5%$71.58+93.4%-32.7%$4.59B$18.47M-7.26250AAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.45B$134.35M0.00600High Trading VolumeKRYSKrystal Biotech4.7192 of 5 stars$146.77-2.5%$210.38+43.3%-26.1%$4.36B$290.52M30.59210ACADACADIA Pharmaceuticals4.0489 of 5 stars$25.32-1.6%$28.88+14.0%+67.1%$4.34B$957.80M19.04510Positive NewsADMAADMA Biologics4.3441 of 5 stars$17.01-4.4%$27.67+62.6%+0.8%$4.25B$426.45M19.78530Positive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.22B$516.72M0.00N/AAnalyst ForecastAnalyst RevisionGap Down Related Companies and Tools Related Companies Nuvalent Competitors Merus Competitors CRISPR Therapeutics Competitors TG Therapeutics Competitors Cytokinetics Competitors Ascentage Pharma Group International Competitors Krystal Biotech Competitors ACADIA Pharmaceuticals Competitors ADMA Biologics Competitors Telix Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access